← Back to Search

Virus Therapy

Study Group 1 for Ebola Sudan Virus Disease

Phase 1
Waitlist Available
Research Sponsored by International AIDS Vaccine Initiative
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6.5 months
Awards & highlights

Study Summary

This trial tests a vaccine's safety & effectiveness in adults to see if it can protect against Ebola.

Eligible Conditions
  • Ebola Sudan Virus Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6.5 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6.5 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate the safety and tolerability of rVSVΔG-SEBOV-GP vaccine
Secondary outcome measures
To determine SEBOV-GP-specific antibody responses induced by rVSVΔG-SEBOV-GP vaccine
Other outcome measures
To explore the characteristics of the immune responses induced by rVSV∆G-SEBOV-GP vaccine

Trial Design

3Treatment groups
Experimental Treatment
Group I: Study Group 3Experimental Treatment1 Intervention
rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10^8 pfu intramuscularly Day 1
Group II: Study Group 2Experimental Treatment1 Intervention
rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10^7 pfu intramuscularly Day 1
Group III: Study Group 1Experimental Treatment1 Intervention
rVSV∆G-SEBOV-GP Vaccine or Placebo Dosage 2 × 10^6 pfu intramuscularly Day 1

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

International AIDS Vaccine InitiativeLead Sponsor
48 Previous Clinical Trials
13,224 Total Patients Enrolled
Biomedical Advanced Research and Development AuthorityFED
81 Previous Clinical Trials
909,405 Total Patients Enrolled
1 Trials studying Ebola Sudan Virus Disease
125 Patients Enrolled for Ebola Sudan Virus Disease

Media Library

rVSVΔG-SEBOV-GP Vaccine (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05724472 — Phase 1
Ebola Sudan Virus Disease Research Study Groups: Study Group 1, Study Group 2, Study Group 3
Ebola Sudan Virus Disease Clinical Trial 2023: rVSVΔG-SEBOV-GP Vaccine Highlights & Side Effects. Trial Name: NCT05724472 — Phase 1
rVSVΔG-SEBOV-GP Vaccine (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05724472 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are geriatric individuals accepted into this medical study?

"The age limit for taking part in this study is 18 to 50, as stated by the official inclusion criteria."

Answered by AI

Are there current opportunities to participate in this experiment?

"Clinicialtrials.gov confirms that this clinical trial is still actively recruiting participants, which began with its post date of June 19th 2023 and was most recently updated on June 20th 2023."

Answered by AI

How many individuals are engaged in this research endeavor?

"Affirmative. The information on clincialtrials.gov displays that this research trial, initially published on June 19th 2023, is currently enrolling patients. To reach their goal of 36 participants, recruiters are operating from two distinct sites."

Answered by AI

Has Study Group 2 been certified by the FDA?

"The team at Power judged Study Group 2 to have a score of 1 on the safety scale, as it is currently in its first phase and more research must be conducted to better ascertain efficacy."

Answered by AI

What criteria must individuals fulfill to qualify for this study?

"This study is accepting 36 individuals with ebola sudan virus disease, aged between 18 and 50. To be eligible for participating in this trial, participants must meet the following criteria: good health status; adherence to protocol requirements; HIV testing and risk counseling; condom use (for male or female patients) as applicable; contraception usage from two weeks before IP administration until three months after vaccine receipt; urine pregnancy tests (as relevant); no organ donation throughout the duration of the study period; any clinically significant acute/chronic medical conditions are excluded."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health
2023. "Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05724472.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top